Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus as continuous infusion

Pediatric Hematology and Oncology

Volumn 27, Issue 7, 2010, Pages 546-557

  Huh, Winston W ^a   Jaffe, Norman ^a   Durand, Jean Bernard ^a   Munsell, Mark F ^a   Herzog, Cynthia E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

anthracycline; cardiotoxicity; doxorubicin; heart failure; sarcoma

Indexed keywords

CARVEDILOL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; RAZOXANE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BOLUS INJECTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG MECHANISM; DRUG MEGADOSE; ECHOCARDIOGRAPHY; EWING SARCOMA; FATALITY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PRESCHOOL CHILD; RACE DIFFERENCE; RETROSPECTIVE STUDY; SCHOOL CHILD; SEX DIFFERENCE; THORAX CANCER; TREATMENT RESPONSE; UNITED STATES;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOXORUBICIN; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OSTEOSARCOMA; RAZOXANE; RETROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR DYSFUNCTION; YOUNG ADULT;

EID: 77957241407     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.503335     Document Type: Article

References (27)

1. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25:S72-S85.
2. van Dalen EC, Van Der Pal HJH, Kok WEM, et al. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42: 3191-3198.
3. Paulides M, Kremers A, Stohr W, et al. Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the Late Effects Surveillance System (LESS). Pediatr Blood Cancer. 2006;46:489-495. (Pubitemid 43334657)
4. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37-44. (Pubitemid 39013042)
5. Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. Cancer. 1990;65:870-873.
6. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991;68:1221-1229.
7. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133-139. (Pubitemid 12172323)
8. Berrak SG, Ewer MS, Jaffe N, et al. Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep. 2001;8: 611-614.
9. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukemia protocol. J Clin Oncol. 2002;20:1677-1682.
10. Gupta M, Steinherz PG, Cheung NK, et al. Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol. 2003;40:343-347. (Pubitemid 36514435)
11. Iarussi D, Indolfi P, Casale F, et al. Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem. 2001;8:1649-1660. (Pubitemid 33076806)
12. Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anti Cancer Agents. 2003;3:151-171. (Pubitemid 36221735)
13. Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362-372. (Pubitemid 26050996)
14. Lipshultz SE, RifaiN,Dalton V, et al. The effect of dexrazoxane onmyocardial injury in doxorubicintreated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145-153. (Pubitemid 38886649)
15. Kremer LCM, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191-196. (Pubitemid 32063496)
16. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545-550. (Pubitemid 28135597)
17. Krischer JP, Epstein S, Cuthbertson DD, et al. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15: 1544-1552. (Pubitemid 27167391)
18. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol. 2006;33:S2-S7. (Pubitemid 43866214)
19. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control. 1999;3:145-159.
20. Tebbi CK, London WB, Friedman D, et al. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25:493-500. (Pubitemid 350002954)
21. van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;(2):CD003917.
22. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127-145.
23. Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139-3148.
24. Van Der Pal HJH, van Dalen EC, Kremer LCM, et al. Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev. 2005;31:173-185.
25. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23: 2629-2636.
26. Sorensen K, Levitt GA, Bull C, et al. Late anthracycline cardiotoxicity after childhood cancer. A prospective longitudinal study. Cancer. 2003;97:1991-1998. (Pubitemid 36397277)
27. Poutanen T, Tikanoja T, Riikonen P, et al. Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21:2349-2356. (Pubitemid 46621873)